Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: Is there CD20 antigen upregulation? Journal Article

Authors: Portlock, C. S.; O'Connor, O. A.; Straus, D. J.; Rosenzweig, L.; Dumitrescu, O.; Lin, O.; Maslak, P.
Article Title: Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: Is there CD20 antigen upregulation?
Abstract: The anti-CD20 monoclonal antibody, rituximab, and interferon alpha (IFN) are active agents in advanced stage, indolent lymphoma. Some data obtained in vitro suggest upregulation of CD20 by IFN, and clinical trials have reported additive or synergistic activity of IFN with rituximab. A prospective phase II study in advanced stage, follicular and non-follicular indolent lymphoma was performed. Peginterferon alpha 2b (pegIFN) 0.5 μg/kg s.c. weekly × 6 and rituximab 375 mg/ m 2 i.v. weekly × 4 (beginning on week 3 of pegIFN) was administered. Quantitative CD20 antigen was measured pre-treatment and pre-rituximab in lymph node aspirates. Nine patients were treated: one complete response and three partial responses; however, all relapsed within 12 months and two were withdrawn for grade 3 toxicity (both with serum sickness). No up-regulation of CD20 was documented in seven patients studied (median change in CD20: decrease by 11.9%). PegIFN plus rituximab as delivered in this study is not recommended. PegIFN does not appear to upregulate CD20 expression in peripheral lymph node tumor cells.
Keywords: adult; clinical article; controlled study; aged; middle aged; prednisone; clinical trial; fatigue; advanced cancer; drug withdrawal; treatment planning; antineoplastic agents; rituximab; cancer staging; lymph nodes; antigen expression; peginterferon alpha2b; controlled clinical trial; drug eruption; phase 2 clinical trial; myalgia; biopsy; arthralgia; drug fever; injection site reaction; maculopapular rash; gene expression regulation, neoplastic; cd20 antigen; antigens, cd20; antibodies, monoclonal; disease severity; nonhodgkin lymphoma; quantitative analysis; drug response; lymphoma; tumor cell; erythema; cancer relapse; upregulation; up-regulation; drug dose regimen; follicular lymphoma; proteinuria; lymph node biopsy; polyethylene glycols; antiviral agents; face edema; interferon alfa-2b; antibodies, monoclonal, murine-derived; indolent lymphoma; serum sickness; pegylated interferon; mouth edema
Journal Title: Leukemia and Lymphoma
Volume: 47
Issue: 7
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2006-07-01
Start Page: 1260
End Page: 1264
Language: English
DOI: 10.1080/10428190600565354
PUBMED: 16923555
PROVIDER: scopus
Notes: --- - "Cited By (since 1996): 8" - "Export Date: 4 June 2012" - "CODEN: LELYE" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Carol Portlock
    178 Portlock
  2. Oscar Lin
    231 Lin
  3. Peter Maslak
    166 Maslak
  4. David J Straus
    205 Straus